Slide 1: Q3 2021 Financial Results
We engineer enzymes to improve health… of people and the planet Q3 2021 Financial Results November 4, 2021
Slide 2: Forward Looking Statements
Forward Looking Statements • These slides and any accompanying oral presentation contain forward-looking statements that involve risks and uncertainties, including Codexis’ guidance on 2021 total revenues, product revenues and product gross margin. These statements relate to future events or our fut
Slide 3: Growth Drivers Continue to Accelerate
Growth Drivers Continue to Accelerate Strong Q3’21 Results Executing on Growth Opportunities Total revenue growth of 100% YOY Sustainable Manufacturing - Pharma: Incremental $15M PO from Pfizer Generic sitagliptin agreements Quarterly product revenue >3X YOY Sustainable Manufacturing - Food: New par
Slide 4: Sustainable Manufacturing: Solid, Growing Base with Expanding Margins
Sustainable Manufacturing: Solid, Growing Base with Expanding Margins Quarterly Product Revenue Largest Annual Product Sale in Company History • Additional ~$15M purchase order secured in 30 August, for an aggregate ~$29M order from Pfizer 25 • Enzyme for late-stage COVID-19 antiviral therapeutic ca
Slide 5: Life Science Tools: High Growth
Life Science Tools: High Growth Codex® Reverse Transcriptase Strong Progress in Q3’21 Enzyme targeting PCR-based and Point-of-Care RNA diagnostics • First commercial sale of Codex® HiFi DNA Polymerase Targeted Key features & benefits for diagnostic applications: • Thermostability ---> Improved proce
Slide 6: Biotherapeutics: CDX-7108 for Exocrine Pancreatic Insufficiency Enters Clinic
Biotherapeutics: CDX-7108 for Exocrine Pancreatic Insufficiency Enters Clinic CDX-7108 is co-owned with Preclinical Clinical Superior in vitro GI stability # of Program Discovery Research IND Enabling Phase I 1 0 CDX-7108 R e a c tio n P ro g re s s 8 2016 1 1 6 Enteric coated PERT 4 2 Non-formulate
Slide 7: Strong Q3 2021 Results
Strong Q3 2021 Results $36.8M $28.7M 76% Q3’21 Total Q3’21 Product Gross Product Margin Revenue +100% Revenue +242% vs. 57% in Q3’20 $119M Cash Available for $32.6M $4.2M Growth. No Debt Performance Novel Enzymes Biotherapeutics $15.2M $13.4M $2.2M R&D Expense SG&A Expense Net Income 7
Slide 8: 2021 Guidance: Product Revenues and Gross Margin Raised
2021 Guidance: Product Revenues and Gross Margin Raised $98-103M $63-66M 68-71% Total Revenue Product Revenue Product Gross Margin
Slide 9: Executing 2021 Corporate Goals and Catalysts
Executing 2021 Corporate Goals and Catalysts ❑ Enzymes for Phase 2 / 3 pharma processes commercialize into new recurring product revenues Sustainable ❑ Continue widening pharma adoption and advancing clients to new CodeEvolver® platform deals Manufacturing ❑ $M+ food enzymes revenues from Tate & Lyl
Slide 10: We engineer enzymes to improve health of people and the planet
We engineer enzymes to improve health… of people and the planet Nasdaq: CDXS www.codexis.com